The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01926834

Enrollment

Registered

2013-08-21

Start date

2013-08-31

Completion date

2014-03-31

Last updated

2013-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Infarction

Keywords

promoting angiogenesis in multiple targets, herbal medicine, traditional chinese medicine, random clinical trial

Brief summary

To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction,test is made by random double-blind controlled.patients with acute cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin group,and health people. The main indexes are the serum level of VEGF, MMP-9 and EPC.The review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function of promoting angiogenesis in multiple targets through this test.

Detailed description

OBJECTIVE: To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after acute cerebral infarction. METHOD: 40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people. Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior treatment,the posttreatment 1th, 3th and 7th day,and tested the level of VEGF, MMP-9 and EPC.Tested the health people one time.

Interventions

DRUGErigeron Injection

Erigeron Injection, 30ml, iv, qd, for 7days

DRUGplacebo

normal saline, 500ml,i.v.,qd, for 7 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients aged no younger than 18yrs * attack within 72 hours * NIHSS score in the 2-25 points * Ischemic Stroke occurred for the first time, or with a history of stroke disease but without sequelae * Signed the informed consents

Exclusion criteria

* patients aged younger than 18yrs * Patients with tumor, coronary heart disease, valvular heart disease, psoriasis, rheumatism, hematologic diseases, infertility, varieties of acute inflammation * Patients with severe cognitive impairment * Refused to cooperate or been unable to cooperation for neurological disorders * Cerebral hemorrhage or hemorrhagic cerebral infarction * Unstable vital signs dued to massive cerebral infarction * Patients with serious heart, liver and renal insufficiency

Design outcomes

Primary

Measure	Time frame
the serum level of VEGF,MMP-9 and EPC	0-7days

Secondary

Measure	Time frame
National Institute of Health of stroke scale	0-7days

Contacts

Primary ContactJianwen Guo, doctor

jianwen_guo@msn.com0086-13724899379

Backup ContactYefeng Cai, master

caiyefeng@126.com(08620)81887233

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026